SEC Form 4 · accession 0001104659-16-127130
Hepion Pharmaceuticals, Inc. · HEPA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Sapirstein
Officer — Chief Executive Officer · Director
Period of report
Jun 13, 2016
Accepted (ET)
Jun 14, 2016 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583771
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $0.99 | Jun 13, 2016 | A | 500,000 | A | — | Jun 13, 2026 | Common Stock | 500,000 | 2,150,000 | D |
Explanation of responses
- F1Options vest in three installments as follows: 166,667 options shall vest on each of June 13, 2017 and 2018 and 166,666 shall vest on June 13, 2019.